biomérieux connection · microbiology labs historically have not had the same level of automation...
TRANSCRIPT
from diagnosis,the seeds of better health
2
4 8
7
1112
Message from bioMérieux
Herb Steward
Executive Vice President
and General Manager,
bioMérieux North America
APRIL 2008 • VOL 5 NO 2C O N N E C T I O NbioMérieux
IN THIS ISSUE
Prin
ted
on re
cycl
ed p
aper
.
Welcome to the April 2008 issue of the bioMérieux Connection newsletter. In this issue, we are highlighting the upcoming 108th American Society for Microbiology (ASM) annual meeting in June.
In past issues of the Connection Newsletter, we discussed the skilled-labor issue in U.S.-based labs. While this issue is still valid, we are also seeing some level of lab consolidation to improve effi ciency and cost effectiveness. Consolidation and the demand for improved effi ciency will drive automation. Microbiology labs historically have not had the same level of automation as Chemistry or other labs, which is why our current focus zeroes in on bringing full automation to the microbiology lab.
bioMérieux’s theme for ASM 2008 is Full Microbiology Lab Automation: Delivering the Future. The more automated microbiology laboratories can become, the better. Today’s microbiologist is expected to do more work, faster, to increase profi tability. We are committed to delivering automated solutions at the pre-analytical, analytical and informatics stages to streamline processes while delivering accurate results. As you will see in this
asM 2008 PreviewCustomer Appreciation Party, BUG Club, Knowledge Forums, and more
Product Spotlight:Automated Instruments
6 Bacteria Road Trip
New bioMérieux Technical Library
Company News
fULL MIcroBIoLoGY
LaB aUToMaTIon
asM 2008 Preview
cUsToMeraPPrecIaTIon
ParTY
MIcroBIoLoGY
aUToMaTIon
asM 2008BooTh #731
asM 2008 Preview2 asM 2008 PreviewasM 2008 Preview
aPPrecIaTIon
worksafe campaign
issue, we will be launching many new solutions at ASM that support this effort. A fully automated microbiology lab will better serve the patient, as well as be cost effective for your institution.
Join us at ASM 2008 to learn more about taking your microbiology lab to full automation. We look forward to seeing you at our annual customer appreciation event – held this year at Fenway Park, the home of the Boston Red Sox. We also plan to refocus our 30th Annual Microbiology User Group event. Hosted by key industry leaders, this year’s event will focus on ID/AST, blood culture and new, pre-analytical solutions. ASM is an important show for our community, and we look forward to seeing you there. z
Sincerely,
Herb Steward
1112
Technical LibraryNew bioMérieux New bioMérieux
bioMérieux odyssey
asM 2008BooTh #731
fULL MIcroBIoLoGY LaB aUToMaTIon
2
COMING EVENTS
ASM2008 Preview
american society for Microbiology 108th General Meeting Boston Convention & Exhibit CenterJune 1-5, 2008bioMérieux Booth #731
Exhibit Dates: June 2-4
customer appreciation Party: June 2, 7:30 p.m., Fenway Park
bioMérieux User Group (BUG cLUB): June 3, 5:00 p.m., Westin Waterfront Hotel, Grand Ballroom
experience The fully automated LabWe are excited to share with you the ultimate integrated experience at the ASM 108th General Meeting. We will show you the benefi ts of our integrated solutions by bringing the microbiology lab to you. Visit us at booth #731 and experience the Automated Microbiology Lab, where you will learn how to enhance, automate and make the most of your lab.
In-Booth Knowledge forumsPlease visit bioMérieux booth #731 June 2nd and June 3rd between 11:15am and 1:45pm to listen to your peers discuss the following topics:
• Hudson Garrett, PDI – Chlorahexadine and Safe Blood Culture Collection
• Christine Ginnochio, Ph.D, North Shore LIJ Health System, – Molecular Automation
• John Glassen, Bioscience Consultant, LabTech – Automated Streaking
• Janet Hindler, MCLS, MT(ASCP), F(AMM), UCLA Medical Center – CLSI Updates: Antibiograms
• Davise Larone, Ph.D, D(ABMM), F(AMM), Cornell University – Galactomann & Beta-Glucan (Non-Culture Based Diagnostic Tests for Fungi)
• Margie Morgan, Ph.D, Chief Microbiologist, Cedar-Sinai Medical Center – Managing Blood Stream Infections
More to come!
KnowLedGe forUMs
The american society
for Microbiology (asM)
is holding the 108th
General Meeting in
Boston, Ma, from
June 1-5, 2008. bioMérieux
is excited to offer a variety
of educational events that will teach you
how to provide better patient care while
improving the clinical value of your lab. In
addition to our traditional asM events, we
have partnered with clinical laboratories
throughout the U.s. to deliver poster
presentations of our research on highly
drug-resistant organisms.
More details to come! Be sure to visit www.biomerieux-usa.com/asm2008 often for updates.
bioMérieux User Group (BUG cLUB)To register for this bioMérieux customer only event, visit www.biomerieux-usa.com/asm2008 and use access code BUGASM
WHEN: Tuesday, June 2nd
WHERE: Westin Waterfront, Grand Ballroom
WHAT: bioMérieux is going back to the basics at our 30th Annual Microbiology User Group. An evening hosted by key industry notables will provide you the opportunity to learn about antibiotic overuse, rapid results and the trends in lab automation.
5:00-6:00 p.m. – Registration, Cocktail and Dinner
6:00-6:05 p.m. – Welcome, Herb Steward, Executive Vice President and General Manager, bioMérieux North America
6:05-6:30 p.m. – Microbiology Update, Doug Flammang, VITEK®/VITEK 2® Project Leader, bioMérieux
6:30-8:00 p.m. – Industry Panel
Blane Schilling, Aspen Consulting – Moderator
George Drusano, Ordway Research – The Lab’s Role in Getting Relevant Results Interpretable Data to the Clinical
Susan Foster, APUA – Economic Impact of the Overuse of Antibiotics, The Trends in Lab Automation
additional Posters at asMbioMérieux and Washington University School of Medicine (St. Louis, MO) will also be presenting two posters at ASM. Look for “Daptomycin and Telavancin MIC Tests for Gram-Positive Organisms with the VITEK 2 Systems” and “Ceftobiprole, Clindamycin, Doripenem, Faropenem, and Televancin MIC Tests for Streptococcus pneumoniae with the VITEK 2 Systems.” z
PrePare YoUr LaB
3
bioM
érie
ux C
onne
ctio
nAp
ril 2
008
Prin
ted
on re
cycl
ed p
aper
.
Prepare Your Lab for BattleReducing the emergence and spread of drug-resistant organisms continues to pose a major challenge to clinical laboratories today. To help combat these emerging disease threats, bioMérieux established the BORIS (bioMérieux Organism Resistance Initiative Surveillance) network to collect and study drug-resistant organisms from participating U.S. clinical laboratories. In collaboration with our network laboratories, we will present two posters of original research from BORIS at this year’s ASM General Meeting in Boston.
Both presentations will address challenges in susceptibility testing of organisms resistant to multiple antimicrobial classes and detection of emerging resistance mechanisms such as AmpC, KPC and metallo-ß-lactamases (MBL). The posters will include our research of the multi-drug resistant organisms Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PA).
For more information about these presentations, visit www.biomerieux-usa.com/connection. z
bioMérieux appreciates YoU! cUsToMer aPPrecIaTIon ParTYWHEN: Tuesday, June 2, 7:30 p.m.
WHERE: fenway Park
WHAT: The opportunity for bioMérieux to appreciate you for the hard word you do all year to make a difference in patient outcomes!
Each year bioMérieux kicks off ASM with a special Customer Appreciation Party. Join us this year for an exciting evening at Fenway Park, Monday, June 2 at 7:30 p.m. Start the night off with an ice-cold beverage in an authentic Boston Red Sox stadium cup! Next, you may want to go check out the Green Monster or visit one of the many buffet stations placed around the Executive Suite.
Once you get your energy off the fantastic food, go and visit the actual Red Sox batting cage and take a cut like the World Series Professionals! When you hit your homerun, you will then have the chance to go and meet one of Boston’s alumni players.
Now that your arms have had a workout, then you can take a tour of the stadium and locker rooms or go and snack on some delicious desserts!
When you want to move back to the Suite you can dance the night away with one of Boston’s favorite bands!
If that isn’t enough…you will leave with an authentic bioMérieux/Boston Red Sox ticket stub to remember the evening…
Please visit www.biomerieux-usa.com/asm2008 to register to attend this bioMérieux customer only event.
event, visit www.biomerieux-usa.com/asm2008
BUG cLUB
4
PRODUCTS
bioMérieux Launches PREVI™ Isola Automated Pre-Pour Media (PPM) Streaker
manually streake
d pl
ate
streaker platemanually stre
aked
plat
e
LabTech Systems, an Australian health care equipment and services company, and bioMérieux signed an exclusive worldwide license agreement for LabTech Systems’ automated pre-poured media (PPM) streaker, PREVI™ Isola.
The fully automated pre-poured media (PPM) streaker is an innovative, patented robotic system for the automation of routine agar plate processing undertaken in microbiology laboratories. This pre-analytical phase still remains manual and time-consuming in most laboratories worldwide. In the current trend of laboratory concentration, there is strong demand for automation that can standardize processes and provide traceability, timesaving and optimized workfl ow, as well as improved safety.
The PREVI Isola will offer:• Greater number of isolated colonies• Customer confi gured set-up and sort• Easy management of bi-plates• Accommodation of up to fi ve different types of media
at one time
LabTech Systems’ patented robotic instrument, which provides a solution at this early stage of the microbiology process, has major synergies with bioMérieux’s pre-poured media range. It also enhances bioMérieux’s current portfolio of automated solutions including BacT/ALERT® for blood culture, VITEK® 2 for identifi cation and antibiotic susceptibility testing and DiversiLab® for microbial typing. z
bioMérieux Launches PREVI™ Color Gram Automated Gram Stainer
bioMérieux and Wescor signed an agreement making bioMérieux the exclusive distributor of PREVI Color Gram for Wescor. With this OEM (original equipment manufacturer) agreement, bioMérieux brings automation to a new level in the pre-analytic process with the unique slide staining technology, PREVI™ Color Gram.
Gram staining is a critical and mandatory test performed in the microbiology laboratory. It is a preliminary step used to differentiate Gram-positive and Gram-negative bacteria. A cumbersome and long procedure, traditional Gram staining requires technical expertise, numerous manual steps and therefore lacks reliability and reproducibility. Wescor’s automated spray technology saves time and enables standardization and accuracy of results. The addition of the Cytopro®
rotor to the slide stainers results in a cytocentrifugation with eight-slide capacity. The innovative technique also improves laboratory workfl ow and generates signifi cant savings for laboratories of all sizes.
The PREVI Color Gram will provide the following benefi ts:• Produce slides that are dry and
ready to read• Reduce reagent usage• Create a cleaner environment
The PREVI Color Gram complements a complete range of fully automated solutions for the microbiology bench, with recent innovations such as the PREVI™ Isola for PPM streaking and Sysmex UF-1000i for urinary screening.
About Centrifugation, Gram and Mycobacteria StainingProperly Gram-stained preparations can quickly give you considerable information that can be applied immediately to patient care. The Gram stain is particularly useful in the presumptive diagnosis of bacterial meningitis, bacterial pneumonia, bacteriuria, gonorrhea, and infections of the brain, lung, abdomen, and wounds.
The Cytopro Cytocentrifuge rotor uses centrifugal force and three unique patented chamber designs to sediment cells onto the slide. With the standard volume (single or dual) chambers, suspension fl uid is simultaneously absorbed into the Cytopad® absorption pad as cells contact the microscope slide. The recently introduced high volume Cytopro Magnum™ chamber is easy to use and also retains the excess fl uid from a suspended sample. z
5
bioM
érie
ux C
onne
ctio
n
streaker plate
Sysmex Corporation and bioMérieux signed an agreement making bioMérieux Sysmex’s global partner for distributing its UF-1000i urinalysis system in microbiology laboratories.
Current urinary screening methods, mainly based on microscope cell numeration, are still very manual, time-consuming and a source of errors. Sysmex developed the fl uorescence fl ow cytometry UF-1000i urinalysis system, a highly standardized and automated solution.
Smart TechnologyUF-1000i is a fully automated, urinary screening system that bases its objective analysis on both physical and chemical particle properties. It uses:• Advanced fl ow cytometry technology with
hydrodynamic focusing• Specifi c fl uorescent dyes for bacteria and sediment• Three high-defi nition, reproducible measurement
signals: size, structure and fl uorescence
High-Quality, Standardized Results• Accurate detection and enumeration of urine
particles (two separate analysis channels for bacteria and sediment)
• Reduced cross-contamination with anti-carryover function and sequential analysis mode
• New second channel for improved bacteria detection• Barcode reader identifi cation of samples
and reagents• Daily Quality Control performed for all the main
parameters (high and low positive controls)
April
200
8Pr
inte
d on
recy
cled
pap
er.
Easy to Interpret• Easy-to-read, color-coded scattergrams and clear-cut
numeric values for a concise overview• User-defi nable fl agging of all the parameters for rapid
result assessment• Rule-based fl agging of UTI information to facilitate
reporting positive results
Time-Saving• Simply Load & Go• Minimum hands-on time – Maximum workfl ow
effi ciency• Results in approximately one minute• Continuous loading function for immediate
processing of samples or series testing with up to 50 positions
• Bi-directional connection to LIS
The UF-1000i urinalysis system complements a complete range of fully automated solutions for the microbiology bench, with recent innovations such as the PREVI™ Color Gram and the PREVI™ Isola for PPM streaking. z
bioMérieux to Distribute Sysmex’s UF-1000i Fully Automated Urinalysis System
6
EDUCATION
are you over-worked, short on time and have a limited travel budget?
we understand your challenges.
we know that you need more than 24 hours in a day, and although we can’t move time, we can bring our
mobile lab to you!
bioMérieux OdysseyAdvancing Diagnostics to Improve Public Health
what: The bioMérieux Odyssey is embarking on a quest across the U.S. with more than 40 stops in cities and towns near you. Odyssey’s mission is to provide industry professionals with innovative training and education on advanced diagnostics solutions that improve public health.
who: Microbiology Lab Professionals, Infection Control Professionals, Phlebotomists, Clinicians, and Healthcare Administration
why: Hands-on training and education is essential for today’s busy lab professional. The bioMérieux Odyssey offers you and your colleagues dynamic options and empowers you to make valued decisions. Visit the Odyssey to learn more about:
• Emerging pathogens and source tracking through strain typing
• Latest developments in blood culture and ID/AST, and ways to rapidly deliver relevant data to clinicians
• Hands on instrument training and educational PACE credits
• The next generation consolidated microbiology lab with advanced automation
• Quality assurance solutions
• New reagent tests and a biomarker for sepsis
• Your role with antibiotic stewardship
• What local experts and key opinion leaders are discovering in your area
come aboard the odyssey to gain industry insights in a relaxed environment with refreshments and our friendly staff in your city.
when: bioMérieux’s Odyssey 2008 Kickoff ScheduleDurham, NC • May 27Columbia, SC • May 29-30Orlando, FL • June 2-3Ft. Lauderdale, FL • June 5Hollywood, FL • June 6Miami, FL • June 9-10Tampa, FL • June 12-13Augusta, GA • June 16Atlanta, GA • June 17Greenville, NC • June 19Chapel Hill, NC • June 20
space is limited, so register now by visiting www.biomerieux-usa.com/odyssey to
reserve space for you and your colleagues. once registered, you will receive notices
about additional tour stops and special offers available to tour guests.
Durham, NC • June 23Birmingham, AL • July 2Jackson, MS • July 3The Woodlands, TX • July 7-8San Antonio, TX • July 10Austin, TX • July 11Irving, TX • July 14-15Ft. Worth, TX • July 16Oklahoma City, OK • July 18Los Angeles, CA • July 23-25San Jose, CA • July 28
Visit www.biomerieux-usa.com/odyssey to see the latest updates to the odyssey schedule.z
7
bioM
érie
ux C
onne
ctio
nAp
ril 2
008
new! bioMérieux Technical Library
PNA FISH™ receives Frost & Sullivan’s Rapid In Vitro Diagnostic Technology Innovation of the Year Award
To access the technical library, please visit www.biomerieux-usa.com and follow these three simple steps to register.
• Read and accept the Conditions of Use
• Enter your Customer Number (If you don’t know your customer number, you may enter your system/site number or your account’s 10-digit telephone number), Institution/Facility Name, City, and State.
• Set up your Login: Create your password (must contain at least six characters, two of which must be numerical digits), Confi rm your password, enter your last name, enter your fi rst name, enter your e-mail address, and select your browsing language.
You will receive an e-mail confi rmation of your registration within 30 minutes of submitting your application.
Please allow up to one business day for your account to be activated. You will receive an e-mail confi rming your account activation. z
bottom-up approach. The analyst team considered AdvanDx’s pace of research and technology innovation and its signifi cance and relevance to the overall industry. The ultimate Award recipient was selected after a thorough evaluation of this research.
The recipient of the Award has excelled based on the following criteria:• Signifi cance of technology in the industry• Potential of technology/products to become an industry standard• Competitive advantage of technology when compared to
competing technologies• Ease of adoption of technology• Breadth of intellectual property related to the innovation (e.g.,
patents, coverage in scientifi c publications, papers and in peer reviewed articles).
For more information, visit www.frost.com. z
1 Ly T, Gulia J, Pyrgos V, Waga M, Shoham S. 2008. Impact upon clinical outcomes of translation of PNA FISH-generated laboratory data from the clinical microbiology bench to bedside in real time. Therapeutics and Clinical Risk Management, in press, dovepress.com/articles.php?journal_id=68
PNA FISH™ received Frost & Sullivan’s 2008 Technology Innovation of the Year Award in the fi eld of rapid in vitro molecular diagnostic technology. The award recognizes how hospitals depend on AdvanDx’s easy-to-use, molecular-based PNA FISH diagnostics to quickly identify bloodstream pathogens in hours instead of days. The rapid PNA FISH results enable laboratories to report critical information to physicians and pharmacists earlier to help optimize therapy and reduce mortality rates for patients affl icted with bloodstream infections.1
Research Methodology and Selection Process CriteriaTo choose The Technology Innovation of the Year Award recipient, Frost & Sullivan’s analyst team conducted a selection process that included primary interviews and extensive primary and secondary research via a
COMPANY NEWS
To access the technical library, please visit
Prin
ted
on re
cycl
ed p
aper
.We are pleased to announce the new bioMérieux Online
Technical Library, accessible exclusively to our
valued customers. Quality Control certifi cates/certifi cates of analysis,
package inserts, user manuals, and material safety data sheets are
all available in the new Online Technical Library.
8
SPOTLIGHT
Last year, bioMérieux launched WorkSafe™, an education
campaign to provide labs and infection control personnel
with resources and educational materials to support best
practices in blood culture collection. WorkSafe is designed
to easily integrate into any facility to improve specimen
collection, transport, storage, and disposal.
It is no secret that many hospitals are reaching critical levels of healthcare-associated infections (HAIs) and increasing cases of sepsis, particularly in immuno-compromised patients. Nearly two million patients in the United States get an infection in a hospital every year. Of these, nearly 90,000 people will die as a result of the HAI.1 Healthcare offi cials are desperate for solutions. Better safety practices and lab automation can help reduce the spread of infection in hospitals.
Automation in the fi eld of blood culture is proven to play a signifi cant role in early detection of positive blood cultures through continuous test monitoring. However, blood culture contamination is a continuous problem. bioMérieux spent the past year taking WorkSafe directly to customers for product training and safety education on BacT/ALERT® 3D, our automated microbial detection system.
bioMérieux’s WorkSafe initiative is designed to provide the tools needed for proper blood culture collection to increase safety and combat rising infection rates, antibiotic resistance and sepsis in hospitals. The campaign includes four phases: collection, testing, culture and care. bioMérieux launched the initiative by providing laboratory professionals with WorkSafe resource kits that included a blood culture collection training video, competency checklist and certifi cation that highlights all four phases of the program.
WorkSafe will teach lab technicians and nursing personnel best practices in all stages of blood culture, from collection to care. The campaign supports the use of plastic blood culture bottles, instead of glass, to decrease the risk of breakage, which can lead to blood and body fl uid exposures, and contact with dangerous materials. There are many safety benefi ts to using plastic instead of glass. For example, the lightweight bottles can be sent through pneumatic tube systems without special holders, without fear of breakage.
Many labs already work with plastic to meet Occupational Safety and Health Administration (OSHA) standards and to comply with its Bloodborne Pathogens Standard. Glass puncture wounds are among the most
WorkSafe receives 2008 Diagnostic Marketing
Association Clinical Creative Communications Award
9
bioM
érie
ux C
onne
ctio
n
The kit eliminates the need for nurses
or phlebotomists to manually pull loose
pieces together for blood culture collection.
common injuries in the medical fi eld, and glass that is contaminated with blood or other potentially infectious materials poses an extreme danger. In most cases, plastic can be easily substituted for glass, therefore, “OSHA makes it clear: using glass in the laboratory when an equivalent plastic alternative is available must be justifi ed in writing.”2
In addition to being break-resistant, plastic weighs one-half to one-third less than glass, offering additional advantages to the lab. Lightweight plastic bottles are easier to carry and put less weight on the phlebotomy tray. Additionally, disposal of biohazardous waste is charged by the pound, making lightweight plastic more cost-effective than glass.
Blood Culture Collection KitThe WorkSafe collection phase, which launched May 2007, features the bioMérieux Blood Culture Collection Kit, which equips hospital workers with one simple kit to follow best practices for blood culture-collection. Each latex-free kit includes BacT/ALERT® Bottles, Smiths Medical Saf-T Holder®
Blood Culture Device, 2” x 2” gauze, alcohol prep pads, bandage, biohazard bag, PDI® Chlorascrub™
3.15% Chlorhexidine Gluconate Swabstick, folded instruction sheet and tourniquet.
The Blood Culture Collection Kit is a WorkSafe best practice for blood collection. The kit is designed to provide a safer and easier process for blood culture collection that can help minimize collection contamination, minimizing the risk of false positives.
The kit eliminates the need for nurses or phlebotomists to manually pull loose pieces together for blood culture collection. The kit also contains a disposal bag so biohazardous materials can be properly disposed.
Successful ImplementationWorkSafe has only been available for one year, and it is already helping many labs improve safety and reduce contamination.
Marshalltown Medical Lab in Iowa implemented the WorkSafe initiative and started using the Blood Culture Collection Kit last fall. Already, the kit is proving to be effective and effi cient.
“I have used the WorkSafe initiative to train nursing staff and phlebotomy/lab staff. I used the Blood Culture Collection video to train our nursing staff, and the sample bottles to train our lab staff. Our contamination rate has dropped from above three percent to roughly one percent,” said Sharon Finch, chief technologist at Marshalltown Medical Lab.
Prior to the Blood Culture Collection Kit, the lab in Marshalltown used SPS tubes to transfer blood samples to the BacT/ALERT 3D, creating the opportunity for contamination. The kit eliminates the need for tubes and saves time for the technician. The reduction in contamination is
important to the hospital because of rising costs associated with longer hospital stays.
Industry RecognitionbioMérieux is the proud recipient of a 2008 Clinical Creative Communication Award from the Diagnostic Marketing Association for the Blood Culture Collection Kit. The kit was recognized for the education and training it provides and won in the category of Professional Relations.
Continued on page 10. [+]
April
200
8Pr
inte
d on
recy
cled
pap
er.
“I have used the WorkSafe initiative to train nursing staff and phlebotomy/
lab staff. I used the Blood Culture Collection video to train our nursing
staff, and the sample bottles to train our lab staff. Our contamination
rate has dropped from above three percent to roughly one percent,” said
Sharon Finch, chief technologist at Marshalltown Medical Lab.
Continued from page 9. [-]
WorkSafe™ Survey ResultsCustomers logged on to www.biomerieux-usa.com/worksafe and took a survey to determine what issues they were experiencing with blood culture contamination. Shown below are key fi ndings from the 121 BacT/ALERT® customers who responded to the survey.
Seventy-two percent were from an urban setting, with 71 percent from not-for-profi t facilities, and 66 percent were from hospitals of 250 beds or less. Less than half were CAP-accredited, and only 45 percent had participated in the Institute for Healthcare Improvements (IHI)’s $5 Million Lives Campaign.
Phlebotomists drew 79 percent of the blood cultures, and nurses only drew 15 percent. Less than half of the respondents have a pediatric facility.
It was rewarding to learn that 90 percent of the respondents collected blood from two different sites and used a two-bottle set for each draw.
Contamination rates were varied as follows:
Coagulase-negative Staphylococcus was the main contaminant.
When surveyed, the majority of the respondents wanted video/DVD training, understandable literature and online training.
The bioMérieux WorkSafe initiative is on target to help facilities reduce blood culture contamination. A second survey will be distributed to these survey respondents to determine contamination rates before and after WorkSafe implementation.
Best-selling author, professional speaker and safety consultant Terry Jo Gile, the Safety Lady®, has helped thousands of laboratorians create safety-savvy laboratories. Her book, Complete Guide to Laboratory Safety – Second Edition, is considered the consummate safety reference tool that is specifi c for clinical laboratories. Contact Terry Jo at www.safetylady.com. z
1 Centers for Disease Control and Prevention. www.cdc.gov.2 Ernst J., Dennis. MT(ASCP), Center for Phlebotomy Education, Inc., Coalition for Phlebotomy
Personnel Standards. Richard Fairfax of OSHA talks about the Bloodborne Pathogens Standard. MLO 2003; 35(2):32-34.
10
FDA Clears bioMérieux’s VIDAS® NT-proBNP Assay
bioMérieux received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market VIDAS® NT-proBNP, a test that aids in the diagnosis of suspected congestive heart failure.
Heart failure is a major healthcare issue, whose frequency is expected to continue to rise in the coming years due to the worldwide aging population and increased survival rate from acute coronary events. It is the leading cause of hospitalization in people over 65 years of age, affecting up to 17 million people worldwide.
In the U.S., fi ve million people suffer from heart failure, and 550,000 new cases are diagnosed each year1.
VIDAS NT-proBNP (N-terminal fragment of B-type natriuretic peptide) is a quantitative marker of heart stress with the potential to detect all stages of heart failure, even the early stages, which can be diffi cult to detect. The test provides objective diagnostic information that helps clinicians distinguish heart failure from other disease states with similar clinical symptoms, such as lung diseases or pulmonary embolism. VIDAS NT-proBNP is a proven marker for heart failure and will provide clinicians with a powerful tool for the management of life-threatening cardiac pathologies.
NT-proBNP can also be used to assess the prognosis of patients with established heart failure or acute coronary syndrome. Its measurement is cost-effective and leads to important healthcare cost-savings as shown by analysis from a study at Harvard Medical School’s Brigham and Women’s Hospital in Boston2 and a pivotal randomized multi-center study in Canada3. The latter study reported a reduction in direct medical costs of 15 percent (USD $949 per patient) when NT-proBNP testing was part of routine assessment of emergency department patients with dyspnea (shortness of breath). z
_<1%
13%
21%
11%
27%
23%
4%
_<1% 1-2% 2-3% 3% 3-5% 5-10% _>10%
CONTAMINATION RATE PERCENTAGE
PER
CEN
T O
F O
RG
AN
IZAT
ION
S
1 Rosamond W, et al. Heart disease and stroke statistics – 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115:e69-e171.
PRODUCT SPOTLIGHT:
11
bioM
érie
ux C
onne
ctio
n
SPOTLIGHT
bioMérieux receives FDA clearance for VIDAS® Troponin I Ultra Assay
bioMérieux received FDA clearance for Troponin I Ultra Assay, a new emergency panel assay for the VIDAS system. Due to its high sensitivity, VIDAS Troponin I Ultra can aid in the diagnosis of myocardial infarction accurately, even at a very early stage.
The VIDAS Troponin I Ultra enables physicians to diagnose and therefore initiate treatment without delay in patients presenting to emergency departments with symptoms of acute coronary syndrome. Furthermore, the VIDAS Troponin I Ultra is one of the fi rst to comply with the National Institute of Standards and Technology (NIST)’s new Standard Reference Materials (SRM) 2921 (human cardiac troponin
complex), which will facilitate the interpretation of results for biologists and medical practitioners.
The VIDAS Troponin I Ultra assay offers the following benefi ts:
• Easy to use: just load and go • Cost effective single test format
• Tests run individually or batched • Gold standard ELISA methodology
• Highly reliable: Mean Time Between Failure (MTBF) > two years z
bioMérieux Receives FDA Clearance for VIDAS® C. diffi cile Toxin A&B Assay
bioMérieux is broadening its infectious disease testing panel following clearance from the U.S. Food & Drug Administration (FDA) for C. diffi cile Toxin A&B (CDAB), used with the automated VIDAS® system.
The VIDAS C. diffi cile Toxin A&B assay offers rapid detection of the C. diffi cile bacterium, which is the most common cause of antibiotic-associated diarrhea in hospitals.
In recent years, the incidence of C. diffi cile has increased and evolving strains can result in pseudomembranous colitis, sepsis and even death.
The VIDAS C. diffi cile Toxin A&B test provides results in 75 minutes, enabling physicians to administer proper treatment and prevent unnecessary patient isolation and outbreaks.
bioMérieux’s VIDAS C. diffi cile Toxin A&B Assay is the only automated test on the market today, making bioMérieux the fi rst company to offer a complete solution for managing C. diffi cile infections, including identifi cation with the API® 20A strip, antibiogram with the ATB™ Anaerobic strip, and bacterial genotyping with the DiversiLab® system. z
April
200
8Pr
inte
d on
recy
cled
pap
er.
11
bioM
érie
ux C
onne
ctio
n
• Highly reliable: Mean Time Between Failure (MTBF) > two years z
Toxin A&B Assay is the only automated test on the market today, making bioMérieux the fi rst company to offer
C. diffi cileinfections, including identifi cation with the
April
200
8
2 Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol. 2006;98:800-5.3 Moe G.W, Howlett J, Januzzi JL, et al. N-terminal Pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure. Primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007;115: 3103-3110.
complex), which will facilitate the interpretation of results for biologists and medical practitioners.
The VIDAS Troponin I Ultra assay offers the following benefi ts:
• Easy to use: just load and go • Cost effective single test format
• Tests run individually or batched • Gold standard ELISA methodology
prevent unnecessary patient isolation
The VIDAS Troponin I Ultra enables physicians to diagnose and therefore initiate treatment without delay in patients presenting to emergency departments with
In recent years, the incidence of
NEW VIDAS® ASSAYS
© 2
008
BIO
MÉR
IEU
X, IN
C. A
PI®, B
acT/
ALER
T®, B
acT/
ALER
T® 3
D, C
YTO
PAD
®, C
YTO
PRO
®, C
YTO
PRO
MAG
NU
M™
, DIV
ERSI
LAB
®, O
BSE
RVA®
, PR
EVI™
CO
LOR
GR
AM, P
REV
I™ IS
OLA
, VID
AS®, V
IDAS
® N
T-PR
OB
NP,
VIT
EK® 2
, VIT
EK® 2
CO
MPA
CT
AND
WO
RKS
AFE™
AR
E R
EGIS
TER
ED T
RAD
EMAR
KS O
F B
IOM
ÉRIE
UX.
AD
VAN
DX
PNA
FISH
™ IS
A T
RAD
EMAR
K O
F AD
VAN
DX,
INC
. CH
LOR
ASC
RU
B™
IS A
TR
ADEM
ARK
OF
PDI.
PRIN
TED
IN U
SA. B
MX-
524-
08.
12
C O N N E C T I O NbioMérieux
bioMérieux Connection is published by bioMérieux, Inc., 100 Rodolphe Street, Durham, NC 27712. Please send address corrections and mailing list additions to [email protected]. For customer service, call toll free 800-682-2666. Please visit our web site at www.biomerieux-usa.com. Please share your comments and suggestions with us through your local account manager or by emailing us at the address above. As always, we thank you for being a bioMérieux customer.
Association of Public Health LabsMay 18-21 • St. Louis, MI
American Society of Microbiology June 1-5 • Boston, MA
American Society of Healthcare PharmacistsJune 8-11 • Seattle, WA
Association for Professionals in Infection ControlJune 15-19 • Denver, CO
Annual Meeting of the American Asso-ciation of Clinical Chemistry (AACC)July 27-31 • Washington, DC
COMPANY NEWS
Printed on recycled paper.
bioMérieux Adds ANC Identification Test Card for the VITEK® 2
bioMérieux recently announced a new addition to the VITEK® 2 test card portfolio. The ANC card will provide an accurate, rapid and automated method for the identification of anaerobes and corynebacteria. There is no other simple automated method available to speciate these organisms that are often time-consuming and difficult to identify.
The VITEK® 2 ANC card can identify 63 species of anaerobes and corynebacteria. The test card is instrument-read and results are available within six hours. Laboratories will need to operate the new test card using AIX 5.01 or PC 3.01 software. The ANC card will be available for VITEK® 2 and VITEK® 2 Compact users in April 2008.
In the current healthcare environment, it is increasingly important for the rapid and accurate diagnosis of infectious diseases. The VITEK 2 is an automated system designed to provide rapid and accurate identification and susceptibility results for most clinically encountered
strains. Anaerobic bacteria represent a significant organism group for both the medical and industrial lab and are often difficult to cultivate and identify accurately.
bioMérieux developed this card to enhance the investment customers have in VITEK 2 technology and improve the identification process for a group of organisms that are typically difficult to identify. The result will be improved productivity in the lab and enhanced utilization of the VITEK 2 system. z
South West Association Clinical Microbiology (SWACM)September 10-13 • St. Louis, MI
American College of Chest Physicians (CHEST)October 25-28 • Philadelphia, PA
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) – 47th Annual October 25-27 • Washington, DC
American College of Emergency PhysiciansOctober 27-30 • Chicago, IL
Association for Molecular Pathology October 30-November 2 • Grapevine, TX
Southeastern Association of Microbiology (SEACM) November 3-6 • Myrtle Beach, SC
American Society of Healthcare PharmacistsDecember 7-11 • Orlando, FL
2008 shows and conferences